MedTrace Logo

HIV A6 Genome In ART Unsuccessful Patients On DOR

NCT05322083 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2022-04-11

No results posted yet for this study

Summary

The aim of the study is to evaluate the efficacy of Doravirine (DOR) in the second-line therapy for patients infected with HIV-1 sub-subtype A6 and its derivatives and having the mutations to previously used drugs

Conditions

  • Virus-HIV

Interventions

DRUG

Doravirine

Doravirine will be given to patients after failure on the first NNRTI regimen.

Sponsors & Collaborators

  • MSD Pharmaceuticals LLC

    collaborator INDUSTRY

  • Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-31
Primary Completion
2023-05-31
Completion
2024-01-31
FDA Drug
Yes

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05322083 on ClinicalTrials.gov